Collectively, these findings suggest that HECTD2 knockdown restores sensitivity to lenvatinib in resistant HCC cells, while HECTD2 overexpression reduces the vulnerability of lenvatinib‐sensitive HCC cells to lenvatinib treatment. Here, HECTD2 is linked to hepatocellular carcinoma.